Our top pick for
Teligent Inc is a drug manufacturers-specialty & generic business based in the US. Teligent shares (TLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Teligent employs 142 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.17|
|52-week range||$0.30 - $1.60|
|50-day moving average||$0.36|
|200-day moving average||$0.49|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.10|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||-46.83%|
|1 month (2021-09-17)||-56.41%|
|3 months (2021-07-19)||-65.31%|
|6 months (2021-04-19)||-68.52%|
|1 year (2020-10-16)||-75.64%|
|2 years (2019-10-18)||-78.51%|
|3 years (2018-10-18)||3.42|
|5 years (2016-10-18)||7.23|
Valuing Teligent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teligent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Teligent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.18. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teligent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Teligent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 million.
The EBITDA is a measure of a Teligent's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$46.3 million|
|Gross profit TTM||$-3,722,000|
|Return on assets TTM||-19.58%|
|Return on equity TTM||0%|
|Market capitalisation||$16.1 million|
TTM: trailing 12 months
There are currently 2.3 million Teligent shares held short by investors – that's known as Teligent's "short interest". This figure is 44.6% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Teligent shares can be evaluated.
Teligent's "short interest ratio" (SIR) is the quantity of Teligent shares currently shorted divided by the average quantity of Teligent shares traded daily (recently around 6.4 million). Teligent's SIR currently stands at 0.36. In other words for every 100,000 Teligent shares traded daily on the market, roughly 360 shares are currently held short.
However Teligent's short interest can also be evaluated against the total number of Teligent shares, or, against the total number of tradable Teligent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Teligent's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Teligent shares in existence, roughly 20 shares are currently held short) or 0.0248% of the tradable shares (for every 100,000 tradable Teligent shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Teligent.
Find out more about how you can short Teligent stock.
We're not expecting Teligent to pay a dividend over the next 12 months.
Teligent's shares were split on a 1:10 basis on 27 May 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Teligent shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Teligent shares which in turn could have impacted Teligent's share price.
Over the last 12 months, Teligent's shares have ranged in value from as little as $0.3 up to $1.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Teligent's is 1.618. This would suggest that Teligent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Teligent, Inc. , a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.